Hepatitis C

Chronic Hepatitis C (CHC) takes one of the leading places in the structure of infectious pathology. There is an unfavorable epidemic situation in the world, connected with the steady increase in the incidence of HCV in all age groups.

Due to the fact that the knowledges about the pathogenesis of Hepatitis C have significantly expanded during last time, the therapy of this disease has been improving as well. Currently, there are various factors that can predict the response to antiviral therapy (AVT), the possible outcomes in the natural course of the disease, what, certainly, expands the possibilities of successful treatment. First of all it is connected with the vast accumulated experience in the use of combine antiviral therapy.
The success of HCV treatment directly depends on the rate of viral load reduction.

In order to maintain the suppression of viral replication long-term combination of AVT is required. A key factor of treatment is the maintenance of scheduled the dosage and frequency of medication by the doctor.

Along with foreign drugs for the treatment of interferon-induced leucopenia a new national drug "Allokin-alpha" is widely used (registration certificate № 002829/01 from 22.09.03), which is a new word in antiviral therapy. It is a synthetic linear cytogenetically oligopeptides with mol. weight of 1265 daltons, consisting of 13L-amino acids, which is anallergic and the active ingredient of which is the alloferon.

The efficiency of the drug was studied in several large randomized studies in various infectious diseases, including Hepatitis B and Hepatitis C. The studies have shown that "Allokin-alpha" has a stimulating effect on the leucopoiesis, increasing the level of blood leukocytes in patients with chronic Hepatitis C, herpes and other viral infections. In the earlier works it has been found that "Allokin-alpha" influences the factors of natural immunity (IFN system, natural killer cells), stimulates phagocytosis, has antiviral activity, this leads to the compensation of secondary immune deficiency manifestations and the imbalance elimination of the immunoreactivity system components at Hepatitis C virus (HCV) activity.

The use of Allokin-alpha for stimulation of leucopoiesis in patients with chronic
viral Hepatitis B and C
Authors: R. G. Myazin

The possibilities of interferon-induced leukopenia correction in patients with chronic
Hepatitis C
Authors: G. V. Sapronov, N. M. Belyaeva, R. G. Myazin

"Allokin-alpha is a new national drug for the treatment of acute viral Hepatitis C"
Authors: F. I. Ershov, M. V. Mezentseva, G. P. Becker.